Loading
Please wait while we load your information from QuoteMedia.
Loading
Please wait while we load your information from QuoteMedia.
Please wait while we load your information from QuoteMedia.
Please wait while we load your information from QuoteMedia.
Please wait while we load your information from QuoteMedia.
As of January 5, 2025 • 6:00 PM ET
As of January 5, 2025 • 6:00 PM ET
Date/Time | Source | News Release |
---|---|---|
01/02/2025 08:52 AM EST | SeekingAlpha | INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025 |
12/30/2024 03:20 PM EST | SeekingAlpha | INmune Bio: XPro Cognitive Readout In Sight, But Mind The Financial Dangers |
11/27/2024 04:30 AM EST | US Earnings Reports | Expected earnings - INmune Bio Inc. |
10/31/2024 08:09 PM EDT | SeekingAlpha | INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript |
10/31/2024 04:12 PM EDT | SeekingAlpha | INmune Bio GAAP EPS of -$0.60 misses by $0.10 |
10/31/2024 10:00 AM EDT | SeekingAlpha | Here are the major earnings after the close today |
10/30/2024 05:35 PM EDT | SeekingAlpha | INmune Bio Q3 2024 Earnings Preview |
10/18/2024 01:16 PM EDT | Stock Traders Daily | (INMB) Technical Data |
09/30/2024 05:04 AM EDT | SeekingAlpha | INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal |
09/27/2024 03:37 PM EDT | SeekingAlpha | Achieve, INmune, Lenz gain on bullish initiations from Raymond James |
Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.